Photo from Yuksel Urun/X
Apr 14, 2024, 10:45
Final pre-spectified overall survival analysis of CLEAR, a phase III study – summarized by Yuksel Urun
Yuksel Urun, Professor in Department of Medical Oncology at Ankara University School of Medicine, shared on X:
“Final pre-specified Overall Survival Analysis of CLEAR, a Phase III Study:
- Final CLEAR trial results: Lenvatinib and Pembrolizumab reduces mortality risk by 21% versus Sunitinib in advanced RCC.
- While median OS is similar, the combo’s lower HR and tight 95% CI underscore its robust benefit over time.
- Medians are just midpoints; consistent benefit and CI (Confidence Interval) matter most?
Any insights from the statistical point?”
Additional information.
Source: Yuksel Urun/X
